127 related articles for article (PubMed ID: 23608675)
1. Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study.
Morgan RM; Steele RJ; Nabi G; McCowan C
J Urol; 2013 Oct; 190(4):1207-12. PubMed ID: 23608675
[TBL] [Abstract][Full Text] [Related]
2. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
[TBL] [Abstract][Full Text] [Related]
3. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
4. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
Konety BR; Bird VY; Deorah S; Dahmoush L
J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
[TBL] [Abstract][Full Text] [Related]
8. Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.
Roberts RO; Bergstralh EJ; Peterson NR; Bostwick DG; Lieber MM; Jacobsen SJ
J Urol; 2000 May; 163(5):1471-5. PubMed ID: 10751860
[TBL] [Abstract][Full Text] [Related]
9. Self-reported prevalence of prostate-specific antigen testing in South Australia: a community study.
Pinnock CB; Weller DP; Marshall VR
Med J Aust; 1998 Jul; 169(1):25-8. PubMed ID: 9695698
[TBL] [Abstract][Full Text] [Related]
10. Physician clinical experience and inappropriate prostate specific antigen screening: evidence from an Asian country.
Kuo NW; Lin HC; Lee HC
J Urol; 2008 Nov; 180(5):1954-8; discussion 1958. PubMed ID: 18801533
[TBL] [Abstract][Full Text] [Related]
11. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
[TBL] [Abstract][Full Text] [Related]
12. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy.
Oh JJ; Jeong SJ; Lee BK; Jeong CW; Byun SS; Hong SK; Lee SE
BJU Int; 2013 Aug; 112(4):E265-71. PubMed ID: 23432960
[TBL] [Abstract][Full Text] [Related]
13. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer incidence and survival in relation to education (United States).
Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment.
Yeboa DN; Guzzo T; Mitra N; Christodouleas JP; Haas NB; Vapiwala N; Armstrong K; Bekelman JE
Urology; 2011 Nov; 78(5):1107-13. PubMed ID: 21943872
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
[TBL] [Abstract][Full Text] [Related]
18. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
[TBL] [Abstract][Full Text] [Related]
19. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
20. Trends in prostate cancer incidence and survival in various socioeconomic classes: a population-based study.
Dutta Roy S; Philip J; Javle P
Int J Urol; 2005 Jul; 12(7):644-53. PubMed ID: 16045557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
